Amgen Inc. Stock News

A new ETF hit the market Tuesday, creating buzz for its exposure to popular weight-loss drugs, while expanding the roster of thematic ETFs available for investors willing to pay up for stock-picking p

Despite his reputation as a growth investor, Peter Lynch offers valuable insights into dividend stocks, too. These insights are often overlooked by many of us due to his success with high-growth stock

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Amgen completes acquisition of Horizon Therapeutics, boosting long-term growth potential. Addition of TEPEZZA, KRYSTEXXA, and UPLIZNA strengthens Amgen's inflammation portfolio and global reach. Amgen

While many Wall Street firms are suggesting short Treasury paper and money markets now, for long-term investors looking for growth and income, healthcare is the place to be for the rest of 2023 and li

Quiver Quantitative, the pioneering company behind an alternative data platform designed for retail investors, has been actively tracking stock market trades made by US Congress members and other poli

Senator Elizabeth Warren, an antitrust hawk, expressed disappointment with the U.S. Federal Trade Commission's decision to allow pharmaceutical firm Amgen to move forward with its acquisition of Horiz

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation.is also a consideration.�

Kristopher Koeller relies on two daily medications to keep his blood pressure under control. They're both generics that have been on the market for decades–the kind of drugs that should be cheap.

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The Dow Jones Industrial Average of blue chip stocks is trading higher for the week, but is still in correction territory, having posted losses in each of the past three months.

Breadth of Research Reflects Amgen's Commitment to Rheumatology Data Include Sjögren's Syndrome, Uncontrolled Gout, Severe Active ANCA-Associated Vasculitis and Psoriatic Arthritis THOUSAND OAKS, Cal

The Health Care Select Sector SPDR Fund NYSEARCA: XLV was down 3.81% in the past month and 8.03% in the past three months. The latest round of pharmaceutical stock earnings isn't helping sector perfor

Amgen AMGN, -2.85% has received approval from the U.S. Food and Drug Administration for Wezlana, its treatment for multiple inflammatory diseases.

The U.S. Food and Drug Administration on Tuesday approved Amgen's biosimilar version of Johnson & Johnson's blockbuster psoriasis treatment Stelara for multiple inflammatory diseases.